Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nat Rev Genet. 2018;19(5):299–310.
CAS PubMed PubMed Central Article Google Scholar
Suravajhala P, Kogelman LJ, Kadarmideen HN. Multi-omic data integration and analysis using systems genomics approaches: methods and applications in animal production, health and welfare. Genet Sel Evol. 2016;48(1):1–14.
Karahalil B. Overview of systems biology and omics technologies. Curr Med Chem. 2016;23(37):4221–30.
CAS PubMed Article Google Scholar
Vucic EA, Thu KL, Robison K, Rybaczyk LA, Chari R, Alvarez CE, et al. Translating cancer ‘omics’ to improved outcomes. Genome Res. 2012;22(2):188–95.
CAS PubMed PubMed Central Article Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17–18):1105–40.
CAS PubMed PubMed Central Article Google Scholar
Parry M, Cowling T, Sujenthiran A, Nossiter J, Berry B, Cathcart P, et al. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation. BMC Med. 2020;18(1):1–9.
Eggener SE, Cifu AS, Nabhan C. Prostate cancer screening. JAMA. 2015;314(8):825–6.
CAS PubMed Article Google Scholar
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.
CAS PubMed Article Google Scholar
Merriel SW, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20(1):1–11.
Heidenreich A, Pfister D, Merseburger A, Bartsch G. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know. Eur Urol. 2013;64(2):260–5.
Taşan M, Musso G, Hao T, Vidal M, MacRae CA, Roth FP. Selecting causal genes from genome-wide association studies via functionally coherent subnetworks. Nat Methods. 2015;12(2):154–9.
PubMed Article CAS Google Scholar
Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013;23(2):159–70.
CAS PubMed Article Google Scholar
Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239–43.
CAS PubMed PubMed Central Article Google Scholar
Dupont WD, Breyer JP, Johnson SH, Plummer WD, Smith JR. Prostate cancer risk variants of the HOXB genetic locus. Sci Rep. 2021;11(1):11385.
CAS PubMed PubMed Central Article Google Scholar
Caspari R, Friedl W, Mandl M, Möslein G, Kadmon M, Knapp M, et al. Familial adenomatous polyposis: mutation at codon 1309 and early onset of colon cancer. Lancet (London, England). 1994;343(8898):629–32.
McKinley JM, Weideman PC, Jenkins MA, Friedlander ML, Hopper JL, McLachlan S-A, et al. Prostate screening uptake in Australian BRCA1 and BRCA2 carriers. Hered Cancer Clin Pract. 2007;5(3):161.
PubMed PubMed Central Article Google Scholar
Mur P, García-Mulero S, Del Valle J, Magraner-Pardo L, Vidal A, Pineda M, et al. Role of POLE and POLD1 in familial cancer. Genet Med. 2020;22(12):2089–100.
CAS PubMed PubMed Central Article Google Scholar
Zhuang Y, Wang H, Jiang D, Li Y, Feng L, Tian C, et al. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis. BMC Cancer. 2021;21(1):380.
CAS PubMed PubMed Central Article Google Scholar
Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28.
CAS PubMed PubMed Central Article Google Scholar
Seifert M, Peitzsch C, Gorodetska I, Börner C, Klink B, Dubrovska A. Network-based analysis of prostate cancer cell lines reveals novel marker gene candidates associated with radioresistance and patient relapse. PLoS Comput Biol. 2019;15(11): e1007460.
PubMed PubMed Central Article CAS Google Scholar
Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56(2):275–86.
CAS PubMed Article Google Scholar
Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci. 2008;105(6):2105–10.
PubMed PubMed Central Article Google Scholar
Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, et al. Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun. 2016;7(1):1–12.
Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat Genet. 2018;50(2):206–18.
CAS PubMed PubMed Central Article Google Scholar
Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (New York, NY). 2008;10(2):177–88.
Tan H-L, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;20(4):890–903.
CAS PubMed Article Google Scholar
Pritchard CC, Offit K, Nelson PS. DNA-repair gene mutations in metastatic prostate cancer. N Engl J Med. 2016;375(18):1804–5.
Shenoy D, Packianathan S, Chen AM, Vijayakumar S. Do African-American men need separate prostate cancer screening guidelines? BMC Urol. 2016;16(1):1–6.
Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580(7801):93–9.
CAS PubMed Article Google Scholar
Brouwer I, Lenstra TL. Visualizing transcription: key to understanding gene expression dynamics. Curr Opin Chem Biol. 2019;51:122–9.
CAS PubMed Article Google Scholar
Pope SD, Medzhitov R. Emerging principles of gene expression programs and their regulation. Mol Cell. 2018;71(3):389–97.
CAS PubMed Article Google Scholar
Marzec J, Ross-Adams H, Pirrò S, Wang J, Zhu Y, Mao X, et al. The transcriptomic landscape of prostate cancer development and progression: an integrative analysis. Cancers. 2021;13(2):345.
CAS PubMed PubMed Central Article Google Scholar
Alkhateeb A, Rezaeian I, Singireddy S, Cavallo-Medved D, Porter LA, Rueda L. Transcriptomics signature from next-generation sequencing data reveals new transcriptomic biomarkers related to prostate cancer. Cancer Inf. 2019;18:1176935119835522.
Solé C, Goicoechea I, Goñi A, Schramm M, Armesto M, Arestin M, et al. The urinary transcriptome as a source of biomarkers for prostate cancer. Cancers (Basel). 2020;12(2):513.
PubMed Central Article CAS Google Scholar
Fabbri M, Girnita L, Varani G, Calin GA. Decrypting noncoding RNA interactions, structures, and functional networks. Genome Res. 2019;29(9):1377–88.
CAS PubMed PubMed Central Article Google Scholar
Eke I, Bylicky MA, Sandfort V, Chopra S, Martello S, Graves EE, et al. The lncRNAs LINC00261 and LINC00665 are upregulated in long-term prostate cancer adaptation after radiotherapy. Mol Ther-Nucleic Acids. 2021;24:175–87.
CAS PubMed PubMed Central Article Google Scholar
Tang Y, Pan J, Huang S, Peng X, Zou X, Luo Y, et al. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling. J Exp Clin Cancer Res. 2018;37(1):1–16.
留言 (0)